HPR190 Evaluating the Impact of the Entry of IVD-R in the Biopharmaceutical Industry, With a Focus on Evidence Requirements and Time to Launch
| Autor: | Acosta Luis, S, Silber, A, O'Hara, M, Stockton, K |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S267-S267 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect